Abecma 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
II/0037/G 
This was an application for a group of variations. 
20/07/2023 
n/a 
B.I.a.1.e - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
change relates to a biological AS or a starting 
material [-] used in the manufacture of a 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
biological/immunological product 
B.I.a.3.e - Change in batch size (including batch size 
ranges) of AS or intermediate - The scale for a 
biological/immunological AS is increased/decreased 
without process change (e.g. duplication of line) 
II/0034 
B.I.a.1.e - Change in the manufacturer of AS or of a 
20/07/2023 
n/a 
starting material/reagent/intermediate for AS - The 
change relates to a biological AS or a starting 
material [-] used in the manufacture of a 
biological/immunological product 
PSUSA/10954
Periodic Safety Update EU Single assessment - 
26/04/2023 
23/06/2023 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202209 
idecabtagene vicleucel 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10954/202209. 
II/0032/G 
This was an application for a group of variations. 
22/06/2023 
n/a 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.d - Change in test procedure for AS or 
Page 2/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
starting material/reagent/intermediate - Substantial 
change to or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
biological AS 
B.I.b.2.d - Change in test procedure for AS or 
starting material/reagent/intermediate - Substantial 
change to or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
biological AS 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IB/0035 
B.I.b.2.e - Change in test procedure for AS or 
08/06/2023 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
R/0029 
Renewal of the marketing authorisation. 
26/04/2023 
08/06/2023 
The CAT and CHMP, having reviewed the available 
information on the status of the fulfilment of Specific 
Obligations and having confirmed the positive benefit risk 
balance, are of the opinion that the quality, safety and 
efficacy of this medicinal product continue to be adequately 
and sufficiently demonstrated and therefore recommends 
the renewal of the conditional MA for Abecma, subject to 
the Specific Obligations and Conditions as laid down in 
Page 3/12 
 
 
 
 
 
 
 
 
 
 
 
IB/0033 
B.I.a.4.z - Change to in-process tests or limits 
01/06/2023 
n/a 
applied during the manufacture of the AS - Other 
variation 
IB/0030/G 
This was an application for a group of variations. 
25/05/2023 
n/a 
Annex II to the opinion. 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.a.1.k - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
B.I.a.1.k - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
B.I.a.1.k - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
B.I.a.1.k - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
Page 4/12 
 
 
 
 
 
 
 
 
 
 
 
the AS -replacement or addition of a site where 
batch control/testing takes place 
II/0027 
B.I.a.1.e - Change in the manufacturer of AS or of a 
26/04/2023 
n/a 
starting material/reagent/intermediate for AS - The 
change relates to a biological AS or a starting 
material [-] used in the manufacture of a 
biological/immunological product 
II/0026 
B.II.d.2.c - Change in test procedure for the finished 
30/03/2023 
n/a 
product - Substantial change to or replacement of a 
biol/immunol/immunochemical test method or a 
method using a biol. reagent or replacement of a 
biol. reference preparation not covered by an 
approved protocol 
II/0022/G 
This was an application for a group of variations. 
30/03/2023 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
Page 5/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.b.2.d - Change in test procedure for AS or 
starting material/reagent/intermediate - Substantial 
change to or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
biological AS 
IB/0025 
B.II.d.2.a - Change in test procedure for the finished 
30/01/2023 
n/a 
product - Minor changes to an approved test 
procedure 
IB/0024/G 
This was an application for a group of variations. 
27/01/2023 
n/a 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.4.a - Change to in-process tests or limits 
applied during the manufacture of the AS - 
Tightening of in-process limits 
IB/0021 
B.I.a.2.a - Changes in the manufacturing process of 
16/12/2022 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
II/0020 
B.I.a.4.d - Change to in-process tests or limits 
15/12/2022 
n/a 
applied during the manufacture of the AS - Widening 
of the approved in-process test limits, which may 
have a significant effect on the overall quality of the 
AS 
II/0019 
B.I.a.2.c - Changes in the manufacturing process of 
15/12/2022 
n/a 
Page 6/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the AS - The change refers to a [-] substance in the 
manufacture of a biological/immunological substance 
which may have a significant impact on the medicinal 
product and is not related to a protocol 
PSUSA/10954
Periodic Safety Update EU Single assessment - 
27/10/2022 
n/a 
PRAC Recommendation - maintenance 
/202203 
idecabtagene vicleucel 
IB/0018/G 
This was an application for a group of variations. 
21/09/2022 
n/a 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.4.a - Change to in-process tests or limits 
applied during the manufacture of the AS - 
Tightening of in-process limits 
IB/0017 
B.I.b.1.b - Change in the specification parameters 
24/08/2022 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
R/0014 
Renewal of the marketing authorisation. 
22/04/2022 
24/06/2022 
Annex II 
The CAT/CHMP, having reviewed the available information 
on the status of the fulfilment of Specific Obligations and 
having confirmed the positive benefit risk balance, is of the 
opinion that the quality, safety and efficacy of this 
medicinal product continue to be adequately and 
sufficiently demonstrated and therefore recommends the 
renewal of the conditional MA for Abecma, subject to the 
Specific Obligations and Conditions as laid down in Annex II 
to the opinion. 
Page 7/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10954
Periodic Safety Update EU Single assessment - 
05/05/2022 
n/a 
PRAC Recommendation - maintenance 
/202109 
idecabtagene vicleucel 
The due date for the remaining SOB referring to study 
KarMMa 3 (MM 003) has been amended due to a protocol 
amendment of the study occurred since approval of the 
Conditional Marketing Authorisation for Abecma, which has 
prolonged the time for the interim analysis and postponed 
the final clinical study report of about 6 month. 
IB/0013 
B.I.a.1.k - Change in the manufacturer of AS or of a 
21/03/2022 
n/a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
IB/0015/G 
This was an application for a group of variations. 
03/03/2022 
n/a 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
II/0010 
Update of section 5.1 of the SmPC in order to update 
27/01/2022 
24/06/2022 
SmPC and 
Summary 
efficacy information based on 24 month follow up 
Annex II 
Based on the 24 months longer follow-up data regarding 
data from the pivotal study submitted during initial 
MAA (BB2121-MM-001: A Phase 2, Multicenter Study 
to determine the Efficacy and Safety of bb2121 in 
Subjects with Relapsed and Refractory Multiple 
Myeloma) listed as a specific obligation in the Annex 
MRD-negative status and  CR and duration of responses 
have been updated in section 5.1 of the SmPC. Specific 
obligation in the frame of the Conditional Marketing 
authorisation has been considered fulfilled and deleted from 
annex II of the product information. For more information, 
Page 8/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
please refer to the Summary of Product Characteristics. 
II and in the RMP; The annex II is updated with the 
proposed deletion of the relevant SOB.  The RMP 
version 1.2 has also been submitted. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
II/0002 
B.I.a.1.e - Change in the manufacturer of AS or of a 
27/01/2022 
n/a 
starting material/reagent/intermediate for AS - The 
change relates to a biological AS or a starting 
material [-] used in the manufacture of a 
biological/immunological product 
II/0009 
Update of sections 4.2 and 4.4 of the SmPC, Annex 
16/12/2021 
20/01/2022 
SmPC, Annex 
SmPC new text 
IID and PIL in order to add statements for the use of 
II and PL 
The product information has been amended to reflect that 
Abecma exceptionally during shortage of tocilizumab 
following the "CAT recommendation for the use of 
CAR-T cell-based therapies in EU during shortages of 
tocilizumab" 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
in the exceptional case where tocilizumab is not available 
due to a shortage that is listed in the European Medicines 
Agency shortage catalogue, suitable alternative measures 
to treat CRS instead of tocilizumab must be available prior 
to infusion. 
For more information, please refer to the Summary of 
Product Characteristics. 
IB/0012/G 
This was an application for a group of variations. 
17/01/2022 
n/a 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.II.b.3.z - Change in the manufacturing process of 
Page 9/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the finished or intermediate product - Other variation 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
II/0005/G 
This was an application for a group of variations. 
16/12/2021 
n/a 
B.I.a.2.c - Changes in the manufacturing process of 
the AS - The change refers to a [-] substance in the 
manufacture of a biological/immunological substance 
which may have a significant impact on the medicinal 
product and is not related to a protocol 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
IB/0008/G 
This was an application for a group of variations. 
19/11/2021 
n/a 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
T/0007 
Transfer of Marketing Authorisation 
04/11/2021 
18/11/2021 
SmPC, 
Labelling and 
PL 
IB/0006/G 
This was an application for a group of variations. 
16/11/2021 
n/a 
B.I.a.2.z - Changes in the manufacturing process of 
Page 10/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the AS - Other variation 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
II/0001/G 
This was an application for a group of variations. 
11/11/2021 
n/a 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.2.d - Change in test procedure for AS or 
starting material/reagent/intermediate - Substantial 
change to or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
biological AS 
IB/0003 
B.I.b.2.z - Change in test procedure for AS or 
05/10/2021 
n/a 
starting material/reagent/intermediate - Other 
variation 
IAIN/0004/G 
This was an application for a group of variations. 
28/09/2021 
18/11/2021 
SmPC, Annex 
A.1 - Administrative change - Change in the name 
and/or address of the MAH 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
II, Labelling 
and PL 
Page 11/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 12/12 
 
 
 
 
 
 
 
